UMB Bank n.a. Lowers Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

UMB Bank n.a. lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMOFree Report) by 5.0% during the fourth quarter, HoldingsChannel.com reports. The fund owned 43,371 shares of the medical research company’s stock after selling 2,296 shares during the quarter. UMB Bank n.a.’s holdings in Thermo Fisher Scientific were worth $23,021,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Savant Capital LLC raised its stake in shares of Thermo Fisher Scientific by 0.5% in the 4th quarter. Savant Capital LLC now owns 3,627 shares of the medical research company’s stock valued at $1,997,000 after acquiring an additional 18 shares in the last quarter. 1776 Wealth LLC raised its position in shares of Thermo Fisher Scientific by 2.4% in the fourth quarter. 1776 Wealth LLC now owns 799 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 19 shares during the period. Sugarloaf Wealth Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 6.9% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after buying an additional 19 shares during the period. Rosenberg Matthew Hamilton raised its holdings in Thermo Fisher Scientific by 3.7% in the 4th quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock worth $279,000 after acquiring an additional 19 shares during the period. Finally, Pacifica Partners Inc. boosted its holdings in Thermo Fisher Scientific by 16.5% during the fourth quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 20 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on TMO shares. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and raised their target price for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Robert W. Baird reissued an “outperform” rating and set a $670.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, December 14th. Citigroup assumed coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They issued a “neutral” rating and a $620.00 price target for the company. Finally, Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a research report on Thursday, February 1st. Five analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $599.00.

Get Our Latest Research Report on TMO

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. In other news, CEO Marc N. Casper sold 5,547 shares of the business’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $550.62, for a total value of $3,054,289.14. Following the sale, the chief executive officer now directly owns 43,608 shares in the company, valued at $24,011,436.96. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at approximately $74,039,491.68. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,277 shares of company stock valued at $28,513,384. Company insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.8 %

NYSE:TMO opened at $576.39 on Thursday. The stock’s fifty day simple moving average is $568.11 and its 200-day simple moving average is $522.46. The firm has a market capitalization of $219.78 billion, a P/E ratio of 37.31, a P/E/G ratio of 2.40 and a beta of 0.80. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82.

Thermo Fisher Scientific (NYSE:TMOGet Free Report) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The business had revenue of $10.89 billion for the quarter, compared to the consensus estimate of $10.73 billion. During the same period last year, the company posted $5.40 EPS. Thermo Fisher Scientific’s revenue for the quarter was down 4.9% on a year-over-year basis. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date is Thursday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.10%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

See Also

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOFree Report).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.